Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Common Equity (2018 - 2025)

Arcturus Therapeutics Holdings' Common Equity history spans 8 years, with the latest figure at $214.0 million for Q4 2025.

  • For Q4 2025, Common Equity fell 11.2% year-over-year to $214.0 million; the TTM value through Dec 2025 reached $214.0 million, down 11.2%, while the annual FY2025 figure was $214.0 million, 11.2% down from the prior year.
  • Common Equity reached $214.0 million in Q4 2025 per ARCT's latest filing, down from $224.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $352.6 million in Q1 2021 to a low of $145.7 million in Q3 2022.
  • Average Common Equity over 5 years is $250.9 million, with a median of $258.9 million recorded in 2021.
  • Peak YoY movement for Common Equity: surged 1976.36% in 2021, then plummeted 47.6% in 2022.
  • A 5-year view of Common Equity shows it stood at $228.2 million in 2021, then increased by 18.45% to $270.3 million in 2022, then rose by 3.03% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 11.2% to $214.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Common Equity are $214.0 million (Q4 2025), $224.6 million (Q3 2025), and $231.1 million (Q2 2025).